Next Lesson - Antivirals
Contents
Abstract
- Antibiotics are classified by their mechanism of action against bacteria. The four main targets are cell wall synthesis, protein synthesis, nucleic acid synthesis (making DNA by replication, or RNA by transcription, which is copying DNA into RNA) and folate metabolism. Rarely, the target is the cell membrane.
β-lactams (penicillins, cephalosporins, carbapenems, monobactams) and glycopeptides (vancomycin) inhibit cell wall synthesis and are bactericidal (they kill bacteria).- Protein synthesis inhibitors: aminoglycosides (gentamicin), macrolides (clarithromycin), tetracyclines (doxycycline), and others.
- DNA, RNA and folate inhibitors: fluoroquinolones (ciprofloxacin), trimethoprim, metronidazole (active against anaerobes, which live without oxygen, and protozoa, which are single-celled parasites), nitrofurantoin (uncomplicated UTI) and rifampicin (tuberculosis, TB, which it treats by blocking RNA synthesis).
- Resistance emerges through chromosomal mutation or horizontal gene transfer (bacteria passing genes to one another by transduction, conjugation or transformation). UK practice prioritises antibiotic stewardship to slow resistance development.
Core
Introduction
Antibiotics are one of the greatest advances in medicine. Drug-resistant bacteria are one of the greatest threats to that advance. The pre-clinical curriculum focuses on understanding antibiotic classes by their mechanism, the spectrum of bacteria they cover, and the rules of stewardship that keep them effective.
The companion infection content is in the SimpleMed Infection subject area. The principles of pharmacodynamics (what a drug does to the body or to a microbe) underlie the distinction between bacteriostatic drugs (which stop bacteria growing) and bactericidal drugs (which kill them).
Principles of Antibiotic Therapy
Bacteriostatic versus Bactericidal
The simplest division of antibiotics is by what they do to the bacterium:
- Bactericidal drugs kill bacteria. Required where the host immune response is impaired (neutropenia, a low neutrophil count; asplenia, having no working spleen; endocarditis, infection of the heart valves or their lining; meningitis; severe sepsis).
- Bacteriostatic drugs stop bacterial growth and rely on the host immune system to clear them. Adequate in immunocompetent hosts (people whose immune system works normally) with most infections.
The same drug can be bacteriostatic at low doses and bactericidal at higher concentrations; the labels are useful but not absolute.
Time-Dependent and Concentration-Dependent Killing
How antibiotics kill bacteria has direct dosing implications:
- Time-dependent killing: killing depends on the proportion of the dosing interval (the time between doses) that the drug concentration stays above the minimum inhibitory concentration (MIC, explained in the next section).
β-lactams are the classic example, which is why they are dosed multiple times daily. - Concentration-dependent killing: high peak concentration matters more than time above MIC. Aminoglycosides are the classic example, dosed once daily at high concentration to maximise killing while allowing time for the kidneys and ears to recover.
MIC and Breakpoints
The minimum inhibitory concentration (MIC) is the lowest antibiotic concentration that prevents visible bacterial growth in vitro (in the laboratory, not in the body). Microbiology laboratories measure MICs. They compare each MIC with the breakpoints for that antibiotic. Breakpoints are threshold values that take into account the antibiotic's pharmacokinetics in humans (how the body absorbs, distributes and clears the drug). They predict whether the bacterium is susceptible at standard doses (S), susceptible only with increased exposure to the drug (I), or resistant (R).
Empirical versus Targeted Therapy
- Empirical therapy: given before culture results are available, based on the most likely pathogens for the clinical syndrome and on local resistance patterns. The choice should cover the likely organisms without being broader than needed.
- Targeted therapy: narrowed once the organism and its sensitivities are known. The transition from empirical to targeted is a core principle of stewardship.
Cell Wall Synthesis Inhibitors
β-Lactams
The largest and most important antibiotic family. All
Four sub-classes:
- Penicillins:
- Natural: benzylpenicillin (penicillin G, IV), phenoxymethylpenicillin (penicillin V, oral). Mainly streptococcal infections, syphilis, dental infections.
- Antistaphylococcal (penicillinase-resistant): flucloxacillin. Penicillinase is an enzyme that some bacteria make to destroy penicillins. Flucloxacillin is not inactivated by it. It is used for infections caused by penicillin-resistant staphylococci, for example cellulitis (skin and soft tissue infection), osteomyelitis (bone infection) and endocarditis. For MRSA (methicillin-resistant Staphylococcus aureus), see Glycopeptides below.
- Aminopenicillins: amoxicillin, ampicillin. Broader gram-positive and some gram-negative cover. (Gram-positive bacteria stain purple in the Gram stain. Gram-negative bacteria stain pink.) Co-amoxiclav adds clavulanic acid (a β-lactamase inhibitor, which blocks the enzyme that destroys β-lactams), extending cover to amoxicillin-resistant organisms.
- Antipseudomonal: piperacillin-tazobactam (Tazocin). Broad cover including Pseudomonas aeruginosa and many gram-negatives. It is one option for hospital sepsis of unknown source. The choice should follow local guidance.
- Cephalosporins: classified by generation. In general, third-generation drugs have more gram-negative activity than second-generation drugs, but are less active than cefuroxime (2nd generation) against gram-positive bacteria, most notably Staphylococcus aureus. The fifth-generation drug ceftaroline has extended gram-positive cover. Examples:
- 1st (cefalexin): UTI, soft tissue.
- 2nd (cefuroxime).
- 3rd (ceftriaxone, cefotaxime): meningitis, severe community-acquired infections.
- 4th (cefepime).
- 5th (ceftaroline): some MRSA cover.
- Carbapenems: meropenem, imipenem, ertapenem. The broadest-spectrum β-lactams, reserved for serious infections including those caused by extended-spectrum β-lactamase (ESBL) producers (bacteria that make enzymes which destroy most penicillins and cephalosporins).
- Monobactams: aztreonam. Active only against gram-negative aerobes; useful in penicillin-allergic patients (low cross-reactivity).
Side effects shared across β-lactams:
- Hypersensitivity: rash to anaphylaxis. Around 10% of UK patients self-report penicillin allergy; true IgE-mediated allergy is much rarer (closer to 1%). Cross-reactivity between penicillins and cephalosporins is around 1-5%; lower with later generations and minimal with carbapenems.
- Gastrointestinal (GI) upset, diarrhoea (including C. difficile).
- Reversible neutropenia (low neutrophil count) and thrombocytopenia (low platelet count).
- Cholestatic hepatitis (liver inflammation with blocked bile flow), particularly co-amoxiclav and flucloxacillin (the latter associated with delayed cholestasis up to weeks after stopping).
- Seizures with high-dose carbapenems.
Glycopeptides
Vancomycin and teicoplanin bind the D-alanyl-D-alanine terminus of peptidoglycan precursors. The precursors are the building blocks of the cell wall, and the terminus is their two-amino-acid end. Binding there prevents cross-linking. Active only against gram-positive organisms (the molecule is too large to cross gram-negative outer membranes).
Used for:
- MRSA infection.
- Severe gram-positive infection in penicillin-allergic patients.
- Endocarditis.
- Oral vancomycin, which is not absorbed significantly, for a first episode of C. difficile infection, whether mild, moderate or severe.
Side effects:
- Nephrotoxicity (kidney damage): the dose-limiting toxicity. Plasma levels are routinely monitored.
- Ototoxicity (damage to the ear and hearing).
- "Red man syndrome": histamine release with rapid IV infusion, producing flushing of the upper body. Reversed by slowing the infusion; not a true allergy.
Protein Synthesis Inhibitors
Bacterial ribosomes (70S, made of 30S and 50S subunits; the S number is a size measure based on how fast a particle settles in a centrifuge) are different enough from human ribosomes (80S) for selective targeting.
Aminoglycosides
Gentamicin, amikacin, tobramycin, streptomycin bind the 30S subunit, causing mRNA misreading. Bactericidal, concentration-dependent killing. Active mainly against aerobic gram-negative organisms; synergistic (works better together) with β-lactams against streptococcal endocarditis and listeriosis (infection with Listeria).
Pharmacokinetic features:
- Polar molecules (they carry an uneven electrical charge, so they cross cell membranes poorly): not absorbed orally; given IV or IM.
- Renally excreted; doses must be adjusted for renal function.
- Concentration-dependent killing: once-daily dosing produces high peak (effective) and low trough (less toxic) concentrations. The trough is the lowest level, just before the next dose.
- Therapeutic drug monitoring (measuring drug levels in the blood to adjust the dose) is mandatory. Modern UK extended-interval ("once-daily") regimens use a single timed blood level taken after the dose. This is plotted on a nomogram (a chart used to read off the dosing interval, e.g. Hartford). Serial U&Es (urea and electrolytes, a blood test) are checked for renal function. Traditional multi-dose regimens used peak and trough levels.
Toxicities:
- Nephrotoxicity: classically reversible.
- Ototoxicity: classically irreversible (cochlear damage affects hearing and vestibular damage affects balance).
- Neuromuscular blockade (weakening of the signal between nerve and muscle): rare, can prolong action of muscle relaxants.
Macrolides
Erythromycin, clarithromycin, azithromycin bind the 50S subunit. Bacteriostatic. Active against gram-positives, atypicals (unusual bacteria that β-lactams do not treat, such as Mycoplasma, Chlamydia and Legionella) and some gram-negatives. Useful as alternative to penicillins in allergy.
Indications: community-acquired pneumonia, atypical pneumonia, Helicobacter pylori (H. pylori, a bacterium that infects the stomach lining and can cause ulcers) eradication (clarithromycin), pertussis (whooping cough), and mycobacterial infection (infection with mycobacteria, the group that includes the bacterium that causes TB).
Side effects:
- GI upset and diarrhoea: macrolides are motilin agonists (they activate motilin receptors, which control gut movement) and prokinetic (they speed up movement through the gut).
- QT prolongation (a longer QT interval on the ECG, which can trigger dangerous heart rhythms): clinically important when combined with other QT-prolonging drugs.
- Cholestatic hepatitis.
- Strong CYP3A4 inhibition (CYP3A4 is a liver enzyme that breaks down many drugs, so blocking it raises their levels): classic clinically important interactions with statins (risk of rhabdomyolysis, the breakdown of muscle), warfarin, ciclosporin, sildenafil and many others. Azithromycin has the weakest effect on CYP3A4.
Tetracyclines
Doxycycline, tetracycline, minocycline, tigecycline bind the 30S subunit. Bacteriostatic. Active against many gram-positives, gram-negatives, atypicals, and some protozoa.
Indications: chest infections (especially with atypical cover), Chlamydia, Lyme disease, acne, malaria prophylaxis (doxycycline), MRSA in some regimens.
Side effects and cautions:
- Photosensitivity.
- Tooth discolouration and bone growth effects: contraindicated in children under 12, in pregnancy and breastfeeding.
- GI upset.
- Chelation (the drug binds metal ions such as calcium, magnesium, iron and aluminium, so less is absorbed): reduced absorption with dairy products, antacids and iron supplements; separate doses by 2 to 3 hours.
- Benign intracranial hypertension (also called idiopathic intracranial hypertension): a rare cause of raised pressure inside the skull. It causes headache and visual disturbance.
- Dairy products reduce the absorption of tetracycline itself, and the manufacturer advises taking it 1 hour before or 2 hours after them. Milk and other food affect the absorption of doxycycline only slightly.
Other Protein Synthesis Inhibitors
- Clindamycin: binds 50S subunit. Active against gram-positives and anaerobes. Used in necrotising fasciitis (a rapidly spreading, life-threatening infection of the tissue under the skin). It additionally suppresses toxin production. High C. difficile risk.
- Linezolid: an oxazolidinone (a class of antibiotics that bind the 50S subunit); active against MRSA and VRE (vancomycin-resistant enterococci). Side effects include thrombocytopenia, peripheral neuropathy, and serotonin syndrome. Linezolid is a weak MAOI (monoamine oxidase inhibitor). It might increase the risk of serotonin toxicity when given with SSRIs (selective serotonin reuptake inhibitors), so check the BNF before combining them.
- Chloramphenicol: broad spectrum but rarely used systemically because of aplastic anaemia (the bone marrow stops making blood cells; this is rare and can be reversible or irreversible) and grey baby syndrome (a serious reaction in newborn babies, a risk if the drug is used in the third trimester of pregnancy). Chloramphenicol eye drops can be used for bacterial conjunctivitis. Most cases get better without treatment, so eye drops are used only when needed.
DNA, RNA and Folate Inhibitors
Fluoroquinolones
Ciprofloxacin, levofloxacin, moxifloxacin inhibit DNA gyrase (topoisomerase II) and topoisomerase IV. Topoisomerases are enzymes that control how bacterial DNA is coiled so that it can be copied. Blocking them prevents DNA supercoiling (the twisting of DNA on itself). Bactericidal, broad-spectrum (gram-positives, gram-negatives including Pseudomonas, atypicals).
Used in: complicated UTI, prostatitis, some gastroenteritis, and anthrax prophylaxis (preventing infection after exposure). Use is restricted (see below). For pyelonephritis (kidney infection), NICE lists ciprofloxacin only if other first-choice antibiotics are unsuitable. For severe community-acquired pneumonia, the NICE first-line antibiotics are co-amoxiclav and clarithromycin, and levofloxacin is only an alternative for people with penicillin allergy.
The MHRA (Medicines and Healthcare products Regulatory Agency, the UK medicines regulator) has issued increasingly stringent restrictions on fluoroquinolones because of:
- Tendinitis and tendon rupture (tendinitis means an inflamed tendon; especially the Achilles tendon), worse in older patients and on corticosteroids.
- Aortic aneurysm and dissection (dissection is a tear in the wall of the aorta): a small increased risk.
- QT prolongation.
- Neurological effects: insomnia, confusion, seizures (lower seizure threshold), peripheral neuropathy.
- C. difficile risk.
- Hypoglycaemia (low blood glucose) and dysglycaemia (unstable blood glucose, high or low).
- Photosensitivity.
As a result, fluoroquinolones must now only be prescribed when other commonly recommended antibiotics are inappropriate.
Sulphonamides and Trimethoprim
These drugs target the bacterial folate pathway. Bacteria (unlike humans) depend on this pathway because they cannot take up preformed folate (folate made elsewhere), so they must make their own. Humans get folate from their diet.
Sulphonamides (sulfamethoxazole) inhibit dihydropteroate synthase.Trimethoprim inhibits dihydrofolate reductase (DHFR), an enzyme in the bacterial folate pathway.- The combination co-trimoxazole (sulfamethoxazole + trimethoprim) blocks two consecutive steps and is bactericidal: used in Pneumocystis jirovecii pneumonia (PCP, a fungal lung infection in people with weakened immunity), for prophylaxis (prevention) and treatment, and in some MRSA infections.
- Trimethoprim alone is one of the two first-choice oral antibiotics in the UK for lower UTI in non-pregnant women aged 16 or over, but only if there is a low risk of resistance. The other is nitrofurantoin.
Side effects: rash (including Stevens-Johnson syndrome, a severe blistering skin reaction), hyperkalaemia (high blood potassium: trimethoprim blocks the epithelial sodium channel, ENaC, in the kidney, as the diuretic amiloride does), bone marrow suppression, photosensitivity. Trimethoprim carries a teratogenic risk (it can harm the developing fetus) in the first trimester because it is a folate antagonist.
Metronidazole
The classic side-effect teaching point is the disulfiram-like reaction with alcohol (disulfiram is a drug used in alcohol dependence that makes alcohol cause unpleasant symptoms): flushing, nausea, palpitations. Patients should be warned to avoid alcohol during treatment and for at least 48 hours after stopping.
Nitrofurantoin
Nitrofurantoin is reduced inside bacteria to multiple reactive intermediates that damage DNA, ribosomes and other targets. Active against most uropathogens (bacteria that cause urinary tract infection). Concentrates in urine but achieves negligible plasma levels; therefore useful only in uncomplicated lower UTI, not in pyelonephritis or systemic infection.
Side effects: GI upset, brown urine, peripheral neuropathy, pulmonary fibrosis with prolonged use, and haemolysis (breakdown of red blood cells) in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency (an inherited enzyme deficiency, carried on the X chromosome, that leaves red cells unable to cope with oxidative stress, which is damage from reactive oxygen chemicals). Avoid if the estimated glomerular filtration rate (eGFR, a measure of kidney function) is below 45 ml/minute (insufficient urinary concentration); avoid at term in pregnancy (haemolytic anaemia in newborn).
Rifampicin
- Orange-red discolouration of urine, sweat, tears (and contact lenses).
- Powerful CYP450 inducer (it speeds up the liver enzymes that break down many drugs): reduces plasma levels of many drugs, including hormonal contraceptives such as the combined oral contraceptive pill. Alternative contraceptive advice should be offered.
- Hepatotoxicity.
The standard initial TB regimen is "RIPE": Rifampicin, Isoniazid, Pyrazinamide, Ethambutol, for 2 months, followed by 4 months of rifampicin and isoniazid alone. Each component has memorable toxicities:
- Isoniazid causes peripheral neuropathy and hepatitis. Pyridoxine (vitamin B6) is given to prevent the neuropathy.
- Pyrazinamide causes hepatitis and hyperuricaemia (high uric acid, which can cause gout).
- Ethambutol causes optic neuritis (inflammation of the optic nerve). Warn patients to report any change in colour vision.
Choosing an Antibiotic by Indication
Diagram: Antibiotic targets in the bacterial cell. The four major mechanism classes are cell wall synthesis (β-lactams, glycopeptides), protein synthesis (50S and 30S ribosomal subunits), nucleic acid synthesis (DNA replication and RNA transcription), and folate metabolism. Key: DHFR, dihydrofolate reductase; PABA, para-aminobenzoic acid; topo IV, topoisomerase IV.
UK first-line empirical regimens (confirm with your local antimicrobial guidance, which takes account of local resistance patterns):
- Uncomplicated UTI in non-pregnant women (per NICE NG109). First choices: nitrofurantoin for 3 days if eGFR is 45 ml/minute or more, or trimethoprim for 3 days if there is a low risk of resistance. Second choices, if symptoms have not improved after at least 48 hours of the first choice or the first choice is unsuitable: pivmecillinam (a penicillin) or fosfomycin.
- Pyelonephritis (per NICE NG111): cefalexin is listed first among the first-choice oral antibiotics. Co-amoxiclav and trimethoprim are included only if culture results are available and the organism is susceptible. Ciprofloxacin is included only if other first-choice antibiotics are unsuitable.
- Community-acquired pneumonia (per NICE NG250): severity is judged clinically, together with the CURB-65 score. CURB-65 gives 1 point each for confusion, blood urea over 7 mmol/litre, respiratory rate of 30 or more, low blood pressure, and age 65 or over. Low severity: amoxicillin. Moderate severity: amoxicillin, with clarithromycin added if atypical pathogens are suspected. High severity: co-amoxiclav plus clarithromycin. In pregnancy, erythromycin replaces clarithromycin. In penicillin allergy, use doxycycline or clarithromycin for low and moderate severity, and levofloxacin for high severity.
- Hospital-acquired pneumonia (per NICE NG250): oral co-amoxiclav if symptoms or signs are not severe and the risk of resistance is not higher. For severe symptoms or signs (for example, signs of sepsis) or a higher risk of resistance, use an intravenous antibiotic. Options include piperacillin-tazobactam, ceftazidime, ceftriaxone, cefuroxime, meropenem, and ceftazidime with avibactam. The choice should be based on specialist microbiological advice and local resistance data.
- Cellulitis: flucloxacillin (clarithromycin if penicillin-allergic).
- Necrotising fasciitis: benzylpenicillin + flucloxacillin + clindamycin + gentamicin (regimens vary).
- Bacterial meningitis: ceftriaxone (add amoxicillin in over-50s and immunocompromised for Listeria cover; add dexamethasone).
- Sepsis of unknown source (per NICE NG253, for people aged 16 or over): broad-spectrum intravenous cover from the local formulary (e.g. piperacillin-tazobactam ± gentamicin). For people at high risk (for example, a NEWS2 score of 7 or above; NEWS2 is the National Early Warning Score 2), give it within 1 hour of calculating the score. For people at medium risk (NEWS2 of 5 or 6), a clinician at foundation year 2 level or above may consider deferring antibiotics for up to 3 hours, to gather information for a more specific diagnosis. These time limits are a maximum, not an aim.
- C. difficile infection (per NICE NG199): oral vancomycin is first-line for a first episode. Fidaxomicin (another oral antibiotic) is second-line if vancomycin is ineffective. It is also used for a relapse, which is a further episode within 12 weeks of symptoms resolving. For a recurrence, which is a further episode more than 12 weeks after symptoms resolve, use vancomycin or fidaxomicin. Metronidazole is not used alone. For life-threatening infection, seek urgent specialist advice. Specialists may initially offer oral vancomycin with intravenous metronidazole.
- Acute sore throat (tonsillitis) (per NICE NG84): use the FeverPAIN or Centor score (clinical scores that identify who is more likely to benefit from an antibiotic). Do not offer an antibiotic for a FeverPAIN score of 0 or 1, or a Centor score of 0, 1 or 2. Consider an immediate antibiotic for a FeverPAIN score of 4 or 5, or a Centor score of 3 or 4. The first-choice antibiotic is phenoxymethylpenicillin for 5 to 10 days.
- Helicobacter pylori: a proton pump inhibitor (PPI) + amoxicillin + clarithromycin (or metronidazole), 7 days.
- TB: RIPE regimen (see above).
Antibiotic Resistance
Bacteria become resistant by two routes:
- Chromosomal mutation: spontaneous changes that confer resistance.
- Horizontal gene transfer (bacteria passing genes to other bacteria):
- Conjugation: transfer of plasmids (small rings of DNA that can be passed between bacteria) by direct cell-cell contact.
- Transduction: transfer via bacteriophage (a virus that infects bacteria).
- Transformation: uptake of free DNA from the environment.
The mechanisms by which bacteria become resistant fall into four broad categories:
- Drug-inactivating enzymes: β-lactamases, carbapenemases (enzymes that destroy carbapenems), aminoglycoside-modifying enzymes.
- Target modification: altered penicillin-binding proteins (MRSA), altered ribosomal target (macrolide resistance), D-Ala-D-Lac (D-alanyl-D-lactate) replacing D-Ala-D-Ala at the end of the cell wall precursors, so vancomycin binds poorly (VRE).
- Reduced drug uptake or active efflux (efflux means pumping the drug out of the cell): tetracycline resistance, fluoroquinolone resistance.
- Bypass of the affected pathway: the bacterium uses another route to make what the drug blocks.
Resistant organisms of particular UK concern:
- MRSA: methicillin-resistant Staph aureus; treat with vancomycin, teicoplanin, linezolid, or daptomycin.
- VRE: vancomycin-resistant enterococci.
- ESBL: extended-spectrum β-lactamase-producing gram-negatives; treated with carbapenems.
- CRE / CPE: carbapenem-resistant / carbapenemase-producing Enterobacterales (gut bacteria such as E. coli and Klebsiella); few options remain (e.g. colistin, ceftazidime-avibactam).
Antibiotic Stewardship
The Start Smart, Then Focus approach is the standard UK framework:
- Start smart:
- Use empirical antibiotics promptly when bacterial infection is likely, and only then.
- Obtain cultures before starting where possible.
- Document the indication, dose and duration.
- Avoid antibiotics for viral infections that are self-limiting (they get better without treatment).
- Then focus: review at 48-72 hours and choose one of five actions (CARES):
- Cease: stop the antibiotic if there is no evidence of infection.
- Amend: change to a narrower-spectrum agent, or a broader one if required.
- Refer: for suitable patients, refer to antimicrobial services outside the ward, such as complex outpatient antimicrobial therapy (COPAT) or virtual wards.
- Extend: continue, and document the next review date or stop date.
- Switch: change from intravenous to oral.
The WHO "AWaRe" classification sorts antibiotics into Access, Watch and Reserve groups to encourage appropriate use. The five key prescribing rules below are separate, general stewardship principles:
- Always use the narrowest-spectrum agent that will work.
- Use the shortest effective duration: UK courses are now generally shorter than they were a decade ago.
- Switch IV to oral as soon as the patient can tolerate oral and is improving.
- Document indication, dose, route, duration and stop date on every prescription.
- Avoid the "4 Cs" (cephalosporins, ciprofloxacin, clindamycin, co-amoxiclav) where alternatives exist, because of C. difficile risk.
Summary
- Antibiotics are classified by the bacterial process they target: cell wall synthesis, protein synthesis, nucleic acid (DNA and RNA) synthesis, and folate metabolism.
- Cell wall: β-lactams (penicillins, cephalosporins, carbapenems, monobactams) and glycopeptides (vancomycin, teicoplanin): bactericidal, time-dependent.
- Protein synthesis:
- Aminoglycosides: concentration-dependent killing. They can damage the kidneys and ears (nephrotoxic and ototoxic), so levels are monitored.
- Macrolides: inhibit CYP3A4 and can prolong the QT interval.
- Tetracyclines: avoid in pregnancy. In children, use only when there is no adequate alternative.
- Clindamycin: active against anaerobes, with a high risk of C. diff.
- Linezolid: used for MRSA and VRE. It is a weak MAOI, so check for interactions such as with SSRIs.
- DNA, RNA and folate:
- Fluoroquinolones: now restricted.
- Trimethoprim: used for UTI. It can cause hyperkalaemia.
- Co-trimoxazole: used for PCP.
- Metronidazole: active against anaerobes. Avoid alcohol during treatment and for at least 48 hours after.
- Nitrofurantoin: used for uncomplicated UTI.
- Rifampicin: used for TB. It inhibits RNA synthesis, turns urine orange and induces CYP enzymes.
- Resistance arises by chromosomal mutation or horizontal gene transfer (conjugation, transduction, transformation); MRSA, VRE, ESBL and CPE are the main UK concerns.
- The "4 Cs" (cephalosporins, ciprofloxacin, clindamycin, co-amoxiclav) carry the highest C. difficile risk.
- Standard TB regimen RIPE: rifampicin (orange urine, CYP), isoniazid (neuropathy: give B6), pyrazinamide (hyperuricaemia, which can cause gout; hepatitis), ethambutol (optic neuritis).
- Antibiotic stewardship: Start Smart, Then Focus; narrow spectrum, short duration, IV-to-oral switch.
Drug Summary Table
Antibiotics organised by mechanism of action.
| Class | Examples | Spectrum / key uses | Key side effects |
|---|---|---|---|
| Penicillins (natural) | Benzylpenicillin (IV), phenoxymethylpenicillin (oral) | Streptococci, syphilis, dental | Allergy, GI upset, C. diff |
| Antistaphylococcal penicillin | Flucloxacillin | Staph aureus: cellulitis, osteomyelitis, endocarditis | Cholestatic hepatitis (delayed) |
| Aminopenicillins | Amoxicillin; co-amoxiclav (+ clavulanic acid) | Community-acquired pneumonia (CAP), UTI, H. pylori; co-amoxiclav broader | Allergy; co-amoxiclav: C. diff, hepatitis |
| Antipseudomonal penicillin | Piperacillin-tazobactam (Tazocin) | Hospital sepsis, neutropenic sepsis, severe infections | As penicillins; C. diff |
| Cephalosporins | Cefalexin (1st), cefuroxime (2nd), ceftriaxone (3rd) | UTI, pyelonephritis, bacterial meningitis (ceftriaxone) | High C. diff risk (one of "4 Cs") |
| Carbapenems | Meropenem, imipenem, ertapenem | Broadest β-lactams; ESBL infections | Seizures (high dose), C. diff |
| Glycopeptides | Vancomycin, teicoplanin | MRSA, severe gram-positive infection, oral vancomycin for C. diff | Nephro-/ototoxicity (monitor levels), red man syndrome |
| Aminoglycosides | Gentamicin, amikacin, tobramycin | Gram-negative sepsis, endocarditis (synergy) | Nephrotoxicity, ototoxicity (monitor levels) |
| Macrolides | Clarithromycin, erythromycin, azithromycin | CAP atypicals, H. pylori; penicillin allergy | GI upset, QT prolongation, CYP3A4 inhibition |
| Tetracyclines | Doxycycline | CAP atypicals, Chlamydia, Lyme, acne, malaria prophylaxis | Photosensitivity; avoid <12 y / pregnancy; chelation with Ca/Fe |
| Lincosamides | Clindamycin | Anaerobes, necrotising fasciitis (toxin suppression) | High C. diff risk (one of 4 Cs) |
| Oxazolidinones | Linezolid | MRSA, VRE | Thrombocytopenia, neuropathy, serotonin syndrome (MAOI) |
| Fluoroquinolones | Ciprofloxacin, levofloxacin, moxifloxacin | Complicated UTI and pyelonephritis (only if other first-choice antibiotics are unsuitable); high-severity pneumonia only as a penicillin-allergy alternative | MHRA-restricted: tendinopathy / rupture, aortic dissection, QT, neuropsychiatric, C. diff, hypoglycaemia |
| Sulphonamide / DHFR inhibitor | Trimethoprim; co-trimoxazole (= sulfamethoxazole + trimethoprim) | Trimethoprim alternative for UTI; co-trimoxazole for PCP | Hyperkalaemia, bone marrow suppression, rash (Stevens-Johnson syndrome, SJS), folate antagonism (teratogenic in the 1st trimester) |
| Nitroimidazole | Metronidazole | Anaerobes, intra-abdominal/pelvic, dental, protozoa (Giardia, Trichomonas) | Disulfiram-like reaction with alcohol; metallic taste |
| Nitrofuran | Nitrofurantoin | First-line uncomplicated UTI (NICE NG109) if eGFR is 45 ml/minute or more | Brown urine, neuropathy, pulmonary fibrosis (chronic), G6PD haemolysis |
| Anti-mycobacterial (TB) | RIPE: Rifampicin, Isoniazid, Pyrazinamide, Ethambutol | Tuberculosis (2 months of RIPE, then 4 months of rifampicin and isoniazid) | Rifampicin: orange urine, CYP inducer. Isoniazid: peripheral neuropathy (give B6), hepatitis. Pyrazinamide: hepatitis, hyperuricaemia (gout). Ethambutol: optic neuritis |
Reviewed by: Dr. Marcus Judge
Quiz
- 266


